Antifungal drug tested against brain cancer — but trial stops early

NCT ID NCT04869449

Terminated Knowledge-focused Sponsor: Milton S. Hershey Medical Center Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This early-phase trial tested whether ketoconazole, a drug normally used for fungal infections, can enter brain tumors in high enough amounts to stop tumor cells from dividing. Only 1 person was enrolled before the study was terminated. The goal was to measure drug levels in the tumor and check safety, but no conclusions can be drawn from such a small, incomplete study.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: ketoconazole (an antifungal drug)
What this could lead to: If successful, this could show whether ketoconazole reaches brain tumors in high enough levels to be studied further as a possible treatment.
What could go wrong: This was a very early phase 0 trial with only 1 participant and was terminated early, so results are extremely limited and may not apply to others.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for GLIOBLASTOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

adult glioblastoma brain cancer brain glioblastoma glioblastoma glioma susceptibility 1

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

GLIOBLASTOMA GLIOBLASTOMA MULTIFORME GLIOBLASTOMA MULTIFORME OF BRAIN GLIOBLASTOMA MULTIFORME, ADULT

Contacts and locations

Show contact details

Locations

Penn State Milton S Hershey Medical Center

Hershey, Pennsylvania, 17033, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.